CSIMarket Company Name, Ticker, Suppliers, else..
 
Aprea Therapeutics Inc   (NASDAQ: APRE)
 

Aprea Therapeutics Inc's Suppliers Performance

APRE's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
APRE Costs vs Sales of Suppliers Growth

• More on APRE Suppliers






Aprea Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers for the production of raw materials, active pharmaceutical ingredients (APIs), and drug products for its product candidates, including APR-1051 and ATRN-119. It does not own or operate current good manufacturing practice (cGMP) facilities and has no plans to develop such capabilities. The contract manufacturers comply with cGMP regulations. The company assesses that current third-party manufacturers have adequate capacity to meet demand and that alternative sources are available if necessary. It plans to identify and qualify additional manufacturers for APIs, drug products, and related services prior to seeking marketing approval. All product candidates are small molecules produced synthetically from readily available starting materials, and their manufacturing processes do not require specialized equipment.

Aprea Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers for the production of raw materials, active pharmaceutical ingredients (APIs), and drug products for its product candidates, including APR-1051 and ATRN-119. It does not own or operate current good manufacturing practice (cGMP) facilities and has no plans to develop such capabilities. The contract manufacturers comply with cGMP regulations. The company assesses that current third-party manufacturers have adequate capacity to meet demand and that alternative sources are available if necessary. It plans to identify and qualify additional manufacturers for APIs, drug products, and related services prior to seeking marketing approval. All product candidates are small molecules produced synthetically from readily available starting materials, and their manufacturing processes do not require specialized equipment.







APRE's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Aprea Therapeutics Inc 41.29 0.00 -12.31 8
SUBTOTAL 0.00 0.00 0.00 -


Sources: Aprea Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Aprea Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.